drugset / Trial / NCT02754726
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2
Completed
35 enrolled
HonorHealth Research Institute
Bristol-Myers Squibb · collabLustgarten Foundation · collabTranslational Genomics Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.
Timeline
- Start
- 2016-04
- Primary completion
- 2023-04-11
- Completion
- 2024-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Paricalcitol | Other / unclassified | 25 ug | Intravenous |